4,105 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by AG2R LA Mondiale Gestion D Actifs

Key Points

• AG2R LA Mondiale Gestion D Actifs has invested approximately $2.60 million in Regeneron Pharmaceuticals by purchasing 4,105 shares during the 1st quarter.
• A recent analysis shows that Regeneron Pharmaceuticals has received a moderate buy rating from Raymond James, with a consensus price target of $817.67 from various analysts.
• Regeneron Pharmaceuticals has reported strong quarterly earnings of $12.89 EPS, significantly exceeding estimates and achieving a revenue increase of 3.6% year-over-year.

AG2R LA Mondiale Gestion D Actifs acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 4,105 shares of the biopharmaceutical company's stock, valued at approximately $2,604,000.

Other hedge funds have also made changes to their positions in the company. Pinney & Scofield Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. boosted its stake in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 31 shares during the period. Activest Wealth Management boosted its stake in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 21 shares during the period. Costello Asset Management INC acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $27,000. Finally, Saudi Central Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $27,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $2.47 during midday trading on Tuesday, reaching $575.06. 707,913 shares of the company traded hands, compared to its average volume of 1,094,070. The firm's 50 day simple moving average is $565.30 and its two-hundred day simple moving average is $577.02. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,165.85. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The firm has a market cap of $60.95 billion, a PE ratio of 14.49, a price-to-earnings-growth ratio of 1.87 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same period last year, the firm earned $11.56 EPS. The company's revenue for the quarter was up 3.6% on a year-over-year basis. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is currently 8.87%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on REGN. Truist Financial decreased their target price on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a research note on Monday, August 11th. BMO Capital Markets raised their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research report on Monday, August 4th. Citigroup restated a "buy" rating and issued a $650.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective for the company. in a research report on Friday, August 1st. Finally, Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a research report on Tuesday, September 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.